BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24447546)

  • 1. [Papillary lesions of the breast].
    Ni YB; Tse GM
    Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
    Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
    Niu F; Wang L; Zhang W; Lyu S; Niu Y
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
    Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
    Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic features of cystic hypersecretory lesion of the breast].
    Bi R; Cheng Y; Yu B; Shui R; Yang W; Xu X
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):25-9. PubMed ID: 24713245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
    Grin A; O'Malley FP; Mulligan AM
    Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary Lesions of the Breast: A Practical Approach to Diagnosis.
    Jorns JM
    Arch Pathol Lab Med; 2016 Oct; 140(10):1052-9. PubMed ID: 27684976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary lesions of the breast.
    Ibarra JA
    Breast J; 2006; 12(3):237-51. PubMed ID: 16684322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of papillary lesions at percutaneous breast biopsy.
    Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A
    Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
    J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
    Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
    Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillary Lesions of the Breast: An Update.
    Wei S
    Arch Pathol Lab Med; 2016 Jul; 140(7):628-43. PubMed ID: 27362568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision.
    Renshaw AA; Derhagopian RP; Tizol-Blanco DM; Gould EW
    Am J Clin Pathol; 2004 Aug; 122(2):217-21. PubMed ID: 15323138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
    Carder PJ; Garvican J; Haigh I; Liston JC
    Histopathology; 2005 Mar; 46(3):320-7. PubMed ID: 15720418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
    Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
    Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
    Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
    Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral cribriform ductal proliferation in the male breast; a mimicker of female cribriform atypical ductal hyperplasia?
    Wang Y; Zhu C; Whitney K
    Histopathology; 2011 Jul; 59(1):148-50. PubMed ID: 21771033
    [No Abstract]   [Full Text] [Related]  

  • 20. Papillary lesions of the breast: imaging findings and diagnostic challenges.
    Jagmohan P; Pool FJ; Putti TC; Wong J
    Diagn Interv Radiol; 2013; 19(6):471-8. PubMed ID: 23996839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.